Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
NEW YORK, March 31, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Aratana Therapeutics, Inc. (NASDAQ:PETX) securities between March 16, 2015 and February 3, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/aratana-therapeutics. There is no cost or obligation to you.
According to the complaint, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (2) therefore, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors regarding the probable timeline for a commercial launch of ENTYCE; and (4) consequently, Aratana’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Aratana you have until April 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/aratana-therapeutics.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
